Clinical outcomes of direct‐acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment
- 17 July 2020
- journal article
- research article
- Published by Wiley in Hepatology Research
- Vol. 50 (10) , 1118-1127
Abstract
Aim: It remains unclear how direct‐acting antiviral (DAA) treatments influence hepatocellular carcinoma (HCC) recurrence and survival in comparison with interferon (IFN).Methods: In total, 338 patients with chronic hepatitis C virus (HCV) infection and previous HCC treatments who initiated IFN (N = 88, IFN group) or DAA treatment (N = 250, DAA group) from January 2005 to November 2017 at 23 hospitals and achieved sustained virologic response (SVR) were analyzed. Cumulative HCC recurrence and survival rates were compared between the two groups using propensity score (PS) matching.Results: After PS matching, 63 patients were selected for each group. The cumulative HCC recurrence rates at 1 and 3 years were 20.6% and 34.6% in the IFN group and 19.2% and 43.0% in the DAA group, respectively; the difference in cumulative HCC recurrence rates between the two groups was not significant (P = 0.332). No significant differences in HCC recurrence patterns were observed between the two groups. Overall survival rates at 1 and 3 years were 100% and 96.6% in the IFN group and 100% and 96.4% in the DAA group, respectively; the difference in overall survival rates between the two groups was not significant (P = 0.132). No significant differences in HCC recurrence and overall survival rates were observed between the two groups in subgroup analyses of patients receiving curative treatment (liver resection or radiofrequency ablation) for the most recent HCC before HCV treatment.Conclusions: The recurrence rates and patterns of HCC and overall survival rates do not differ between SVR patients receiving IFN and DAA treatments.Keywords
Funding Information
- Gilead Sciences
This publication has 32 references indexed in Scilit:
- Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis CHepatology Communications, 2018
- High efficacy of direct‐acting anti‐viral agents in hepatitis C virus‐infected cirrhotic patients with successfully treated hepatocellular carcinomaAlimentary Pharmacology & Therapeutics, 2018
- Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study GroupJournal of Gastroenterology, 2018
- Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinomaJournal of Hepatology, 2017
- Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antiviralsJournal of Hepatology, 2016
- Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapyJournal of Hepatology, 2016
- Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma-A retrospective multicenter studyJournal of Medical Virology, 2015
- Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus‐related hepatocellular carcinomaHepatology Research, 2012
- Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinomaInternational Journal of Clinical Oncology, 2010
- Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinomaAlimentary Pharmacology & Therapeutics, 2010